Chiesi Group said today that the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended that the EMA approve its extra-fine triple combination inhaler for the treatment of chronic obstructive pulmonary disease.
The Trimbow device combines an inhaled corticosteroid, a long-acting beta2-agonist and a long-acting muscarinic antagonist. The healthcare group said it is the 1st time the extra-fine triple therapy has been available in a single inhaler.
Get the full story at our sister site, Drug Delivery Business News.
The post Triple-combo inhaler for COPD wins recommendation for approval in EU appeared first on MassDevice.